| Fiscal Year End | Company Status | Exempt Flag |
| December 31 | Trading | N |
|
|
|
|
|
| Incorporation Locations |
| Inc. Date | Expiry Date | Country | Region | Description |
| 7/Mar/2006 | | Canada | British Columbia | |
|
|
| Exchange Filing Office |
| Location |
| NEX Service Office |
|
|  |
| Business Type(s) |
| Primary/Secondary | Business Type | Details |
| Primary
| Technology
| News Release September 25, 2014 - Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura(TM) for skin cancer detection and the Verisante Core(TM) series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform, while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. Aura(TM) has been approved for sale in Canada, Europe and Australia. Core(TM) has not yet been approved for sale.
|
|
|
| Securities |
| Symbol | Security Name | Market | Status |
| VER.H | Verisante Technology, Inc. | TSX Venture | TRADING |
|
|
| Name History | From | To |
| Verisante Technology, Inc. | 18/Jan/2011 | Present |
|
|
| Company Facts Reconciliation |
| Subject | Date Returned |
| Spring 2015 CFR | Not Received |
|
|
|
|
|
